🇺🇸 FDA
Patent

US 11040027

Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

granted A61KA61K31/437A61K31/501

Quick answer

US patent 11040027 (Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death) held by HEPAREGENIX GMBH expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HEPAREGENIX GMBH
Grant date
Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/437, A61K31/501, A61P, A61P1/16